본문 바로가기
KERD
논문KCI 등재

A Clinical Study of Adverse Reactions afterTaking Mefloquine

김재윤|김경은|김승수|신형식|박태수|방지환|이호준
대한감염학회 (The Korean Society Of Infectious Diseases)|2007.06|Infection and Chemotherapy|제39권 제3호|pp. 159-164

1

조회

0

다운로드

1

인용

0

참고문헌

주제분류내과학

초록

목 적 : Mefloquine은 말라리아 예방약으로 널리 사용되고 있지만 복용 후 부작용이 심하게 발생할 것을 염려하여 예방약을 제대로 복용하지 않으려는 경향이 있다. 이에 mefloquine 복용 이후 발생하는 여러 가지 부작용에 대한 임상적 고찰을 후향적으로 시행하여 해외여행자들에게 부작용에 대한 적절한 대처방법 및 안전한 복용방법을 제공하고자 이 연구를 시행하였다. 재료 및 방법 : 2006년 5월 1일부터 10월 30일까지 국립의료원 해외여행자 크리닉을 방문한 여행자들 중 mefloquine 복용자들을 대상으로 mefloquine 복용한 날 부터 해외출국 전까지 3일 간격으로, 귀국한 후 1주일 간격으로 4회 전화면담을 시행한 후 약제복용과 증상과의 관련성에 대하여 평가하였다. 결 과 : Mefloquine 복용 후 총 393명 중 73 (18.6%)명의 여행자에게서 부작용이 발생하였으며 그 중 남자가 38 (52.1%)명, 여자가 35 (47.9%)명이었으며, 98 (24.9%)건의 부작용이 있었다. 가장 많은 부작용은 열감이었다. 부작용은 mefloquine 복용 시작 3주 이내에 대부분(96%) 발생했으며, 성별 및 연령 간의 유의한 차이가 없었다. 증상을 호소한 대부분의 여행자들은 치료를 받지 않거나 보존적인 치료에 증상이 호전되었다. 많은 여행자들은 mefloquine 복용과 동시에 다른 약을 복용하고 있었거나 백신을 접종하였으며 단지 갑상선 저하증 약을 복용한 경우만이 mefloquine 복용 후 발생한 부작용과 유의한 연관성이 있었다(P<0.05). 결 론 : Mefloquine 복용 후 18.6%의 여행자에게서 부작용이 발생하였으며 현재까지 malaria 발병이 보고된 예가 없어 일차적인 예방약제로 안전하게 사용할 수 있을 것으로 사료된다.

Abstract

Background : Mefloquine is widely used for a chemoprophylactic agent against malaria, however, there is a tendency to avoid mefloquine as preventive medicine due to its side effects. Therefore, we carried out this study to provide travelers with safety information regarding consumption of mefloquine through a prospective research for adverse reactions. Materials and Methods : The study had been estimated for the relationship between administration of mefloquine and symptoms of which person had been prescribed of mefloquine at the International Clinic of National Medical Center from May 1, 2006 to October 30, 2006 by phone interviews every three days prior to departure and 4 times every week following a return from the travel. Results : Adverse reactions had been reported in 73 (18.6%) persons among 393 travelers who had taken mefloquine with the figure of 38 (52.1%) males, 35 (47.9%) females and 98 (24.9%) occurrences of adverse reactions. The most common adverse reaction was febrile sensation. Most (96%) of adverse reactions had been detected in 3 weeks after being taken mefloquine and there was no difference between sex and age. Most of travelers who had complained the symptoms got better spontaneously or through the symptomatic treatment. Some travelers had taken other medicines and had gotten several vaccinations concurrently. Only 3 cases that took medicine for hypothyroidism were related to adverse reactions of mefloquine (P<0.05). Conclusion : There were adverse reactions which were reported in 18.6% of travelers after taking mefloquine and malraria hasn't occurred. So mefloquine is considered as a primary preventive agent against malaria.

참고문헌 (31)

  1. McEvoy, Gerald K, "AHFS Drug nformation 2006", pp.862~868 (2006), American Society of Health- System Pharmacists
  2. Albright TA, "Side Effects of and Compliance with Malaria Prophylaxis in Children", 9, pp.289~292 (2002)
  3. Jong EC, "Current Drugs for Antimalarial Chemoprophylaxis:A Review of Efficacy and Safety", 8, pp.S48~S56 (2001)
  4. Corbett EL, "Adverse events associated with mefloquine.Study in returned travellers confirms author's findings", 313, pp.1~3 (1996)
  5. Croft AM, "Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial", 91, pp.199~203 (1997)
  6. Huzly D, "Malaria chemoprophylaxis in German tourists:a prospective study on compliance and adverse reactions", 3, pp.148~155 (1996)
  7. Croft AM, "Toxicity of mefloquine is similar to that of other chemoprophylaxis", 311(191) (1995)
  8. Hopperus Buma AP, "Long term malaria chemoprophylaxis with mefloquine in Dutch Marines in Cambodia", 173, pp.1506~1509 (1996)
  9. Ohrt C, "Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial", 126, pp.963~972 (1997)
  10. Ki HK, "Incidence of mefloquine- related adverse reactions in Korean travelers", 18, pp.299~306 (2000)
  11. Croft AMJ, "Neuropsychiatric reactions with mefloquine chemoprophylaxis", 347(326) (1996)
  12. Barrett PJ, "Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis:postal and telephone survey of travelers", 313, pp.525~528 (1996)
  13. Shanks GD, "Modern Malaria Chemoprophylaxis", 65, pp.2091~2110 (2005)
  14. Baird JK, "Effectiveness of Antimalarial Drugs", 352, pp.1265~1277 (2005)
  15. Cayley WE, "Mefloquine for Preventing Malaria in Nonimmune Adult Travelers", 69, pp.521~522 (2004)
  16. Taylor WR, "Antimalarial Drug Toxicity", 27, pp.25~61 (2004)
  17. Potasman I, "Neuropsychiatric Problems in 2,500 Long-Term Young Travelers to the Tropics", 7, pp.5~9 (2000)
  18. Van Riemsdijk MM, "Spontaneous reports of psychiatric adverse effects to mefloquine in the Netherlands", 44, pp.105~106 (1997)
  19. Steffen R, "Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa", 341, pp.1299~303 (1993)
  20. Weinke T, "Neuropsychiatric side effects after use of mefloquine", 45, pp.86~91 (1991)
  21. Meier CR, "The Risk of Severe Depression,Psychosis or Panic Attcks with Prophylactic Antimalarials", 27, pp.203~213 (2004)
  22. Borruat FX, "Prolonged Visual Illusions Induced by Mefloquine (Lariam): A Case Report", 8, pp.148~149 (2001)
  23. Palmer KJ, "a review of its antimalarial activity", pp.430~45 75 (1993)
  24. Ellis CJ, "On achieving consensus on the prevention of malaria", 41, pp.4~6 (1998)
  25. MacArthur JR, "Relationships between mefloquine blood levels,gender,and adverse reactions", 66, pp.445~ (2002)
  26. Wiedermann G, "Relationships between mefloquine blood levels,gender,and advers reactions", 66, pp.445~446 (2002)
  27. van Riemsdijk MM, "Neuropsychiatric events during prophylactic use of mefloquine before travelling", 58, pp.441~445 (2002)
  28. Croft AM, "Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?", 2(6) (2002)
  29. Croft A, "Mefloquine to prevent malaria:a systematic review of trials", 315, pp.1412~1416 (1997)
  30. Bem JL, "Mefloquine prophylaxis:an overview of spontaneous reports severe psychiatric reactions and convulsions", 95, pp.167~79 (1992)
  31. Lobel HO, "Long-term malaria prophylaxis with weekly mefloquine", 341, pp.848~51 (1993)

관련 논문AI추천

해외여행자의 Atovaquone-proguanil 순응도강효성, 권낙현, 김성훈, 김재윤, 노혜진, 박태수, 방지환, 신형식, 황래석대한감염학회 · Infection and Chemotherapy2008 · 제40권 제5호Imported Malaria in Korea: a 13-Year Experience in a Single Center권기태, 류성열, 백경란, 송재훈, 신상엽, 정동식, 정두련, 허상택, Hae Suk Cheong, Ji-Young Rhee대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2009 · 제47권 제3호A Study on the Adverse Events of the Yellow Fever Vaccine at an International Travelers’ Clinic김승수, 김재윤, 김태희, 박향미, 방지환, 신형식, 신혜정, 이재요대한감염학회 · Infection and Chemotherapy2009 · 제41권 제3호군내 삼일열 말라리아 반복 입원 환자 분석석웅, 고동훈, 김신수, 김창수, 김창훈, 소병조, 조영기, 최병섭대한내과학회 · 대한내과학회지2005 · 제68권 제6호Hydroxychloroquine 치료 후 38일과 40일에 재발한 삼일열 말라리아 2예엄태현, 정재원, 조종래대한임상미생물학회 · Annals of Clinical Microbiology2005 · 제8권 제2호Travel Pattern and Prescription Analysis at a Single Travel Clinic Specialized for Yellow Fever Vaccination in South Korea김재윤, 이명희, 진범식, Sara Gianella대한감염학회 · Infection and Chemotherapy2016 · 제48권 제1호

이 간행물의 다른 논문 (10건)

혈액배양검사의 원리와 실제김백남pp. 111-116국내 지역사회병원에서 감염내과에 입원하는 환자의 특성박상원pp. 117-1241차 의료기관에서 코감기에 처방한 항균제김은실, 이진수, 정형준, 정문현, 이훈재pp. 125-132Vancomycin-Resistant Enterococcal Bacteremia in a Hematology Unit: Risk Factors for Mortality and Impact of Adequate Antimicrobial Therapy on Mortality최상호, 김양수, 이상오, 전민혁, 전재범, 우준희, 권현희, 최성호, 이상록pp. 133-141국내 HIV 감염자에 있어서 Highly Active Antiretroviral Therapy (HAART)의 치료효과 및 영향분석김연아, 최준용, 김준형, 김영근, 신소연, 박윤선, 김명수, 김준명, 구남수, 송영구pp. 142-150
원문 보기